

Eli Lilly And Co


NASDAQ : LLY

 12M Target Price (Bloomberg)
995.06 USD

- Eli Lilly And CO (LLY) is a Multinational pharmaceutical focuses on oncology, diabetes, immunology, neurodegeneration, and pain which made LLY diversified portfolio reduces reliance on a single therapeutic area.
- LLY key product such as Prozac(depression drugs), Cialis, Zyprexa, Mounjaro and Trulicity (Type 2 diabetes) If we break down revenue by product. Its largest product is a Trulicity which contribute around 20% of revenue followed by Mounjaro which are sold and production all over the globe.
- Recently, LLY received FDA approval for Zepbound, a significant advancement in obesity treatment that positions the company competitively against products like Wegovy (Novo Nordisk).
- However, President Donald Trump has warned drugmakers of impending tariffs, suggesting that companies consider relocating manufacturing to the U.S. This situation may pressure LLY and raise concerns regarding drug pricing, potentially affecting the company's profit margins.
- LLY has announced plans to acquire The Farnesoid X Receptor (FXR) program from clinical-stage biotech Organovo, which focuses on MASH* This acquisition could provide long-term benefits for the company's growth.

*MASH=MetabolicDysfunction-Associated Steatohepatitis

Revenue – Net Profit – %Growth (yoy)



Fundamental Outlook

LAST PRICE	901.8
MARKET CAP (Bil.\$)	855.06
P/E	58.7
P/BV	60.2
Dividend Yield (%)	0.69

Technical Outlook

Support	840.00	800.00
Resistant	940.00	975.00
Take Profit	975.00	1,050.00
Stop <	790.00	



เปิดบัญชีลงทุน Global Trade กับ AIRA ได้ที่นี่

AIRA Research

ณรงค์เดช จันทรไพศาล #066063 Tel. 022681717

พิพล สุรัตนวิช ผู้ช่วยนักวิเคราะห์

วรัทกร เบญจาทูการักษ์ ผู้ช่วยนักวิเคราะห์

